During our research, it was evidenced that European viral vector-based drug developers are currently facing major bottlenecks in the following areas:

Viral vector characterisation and analytical technologies to enable optimal formulation and assay selection

Up- and downstream process development optimisation

Securing the right long-term partners, specifically CDMOs, who can offer platform technologies to support seamless scale-up, large scale cGMP production and tech transfer

Finding the right equipment providers for advanced viral vector manufacturing – from lab to pilot to GMP scale

This is why this summit united  60 + Process Development professionals in June at the Viral Vector Formulation & Process Development Europe Summit to discuss and share innovations to overcome these challenges.

This community active seeks to find long-term partners to assist them in accelerating pipeline progression and speed-to-patient.

If you can lend a helping hand, this is the perfect forum for you to:

Showcase your solutions to a selected group of audience from viral vector-based vaccine, cell and gene therapy process development

Learn and hear biopharma’s pain points and align your services and capabilities to meet their expectations

Raise your brand awareness as the go-to provider and further differentiate your technologies in the crowded marketplace

"Great opportunity to network within the industry and learn a lot in a short amount of time."

Senior Regional Marketing Manager, Akoya Biosciences

Events in the Series